Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Coherus Launches, Signs A Partner

by Ann M. Thayer
May 14, 2012 | A version of this story appeared in Volume 90, Issue 20

Coherus BioSciences has been launched to follow a new approach to producing generic biotherapeutics, or biosimilars, for global markets. A team of process development scientists with experience at several leading biotech and drug firms founded the Redwood City, Calif.-based firm. To increase speed to market and cut costs, Coherus will operate through drug development, clinical research, and manufacturing partnerships. Its first deal is with Japan’s Daiichi Sankyo to develop biosimilar versions of the autoimmune drugs etanercept and rituximab in Asia. Coherus says its pipeline includes five oncology and inflammatory disease therapeutics drugs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.